Alliance study chair and lead author Matthew Wieduwilt, MD, PhD, Professor of Cancer Medicine at Wake Forest University School of Medicine (IMAGE)
Caption
The results of Alliance A041703 Cohort 1, published in the Journal of Clinical Oncology, focused on treating patients aged 60 years and older with newly diagnosed B-cell acute lymphoblastic leukemia (ALL) with immunotherapy medications inotuzumab ozogamicin and blinatumomab. Historically, this group has faced poor outcomes with traditional chemotherapy due to high rates of treatment-related death and relapse.
“Our study shows that targeted immunotherapy is an excellent treatment option for older patients with acute lymphoblastic leukemia,” said Alliance study chair and lead author Matthew Wieduwilt, MD, PhD, Professor of Cancer Medicine at Wake Forest University School of Medicine. “This is a major step forward as we were able to effectively treat the leukemia without conventional chemotherapy, which is often too toxic for older adults.”
Credit
Wake Forest School of Medicine
Usage Restrictions
No restrictions.
License
Public Domain